BioBiz Buzz
BioBiz Buzz
Podcast Description
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries. Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences. Disclaimerhttps://biobizbuzz.com/disclaimer/
Podcast Insights
Content Themes
The podcast focuses on biotechnology, pharmaceuticals, and medical technology, with episodes highlighting significant themes like scientific advancements, emerging technologies, and market trends. Examples include the novel ED treatment with Dicot Pharma's LIB-01, Cereno Scientific's epigenetic approaches to rare cardiovascular diseases, and innovations in CRISPR technology with Caszyme.

BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
What transforms a promising scientific opportunity into a viable biotechnology company?
In this episode of BioBiz Buzz, Mike Ward speaks with Dr Jonathan Talbot, CEO of Melodia Therapeutics, co-founder and former CEO of Mosanna Therapeutics, and winner of the 2026 Strüngmann Award. The award recognises life-sciences entrepreneurs who combine scientific insight with the strategic and operational ability to translate innovation into successful products and companies.
Jonathan Talbot explains why some promising programmes are left behind by large pharmaceutical companies, how entrepreneurs can distinguish a genuinely underappreciated asset from one that should remain on the shelf, and why every development plan must be connected to a credible financing strategy and clearly defined value-inflection points.
Drawing on his experience building Mosanna around an intranasal therapy for obstructive sleep apnoea, he discusses the importance of starting with unmet patient need, defining the target product profile, testing the central development hypothesis and matching capital to meaningful clinical milestones. He also reflects on the leadership lessons learned while raising more than $80 million and preparing the programme for clinical development.
The conversation also explores Melodia’s development of MLD-151, a next-generation, non-covalent and reversible DPP1 inhibitor intended for severe neutrophil-driven inflammatory diseases. Jonathan Talbot describes how a biomarker-led Phase I programme could help determine whether the candidate has a differentiated pharmacological and therapeutic profile.
Above all, this is a conversation about biotech company building: resilience, investor alignment, capital strategy, decision-quality data and the CEO’s responsibility to create an environment of trust and candour. Jonathan Talbot also sets out his ambition for a European biotech ecosystem with more founders prepared to build globally competitive companies, deeper pools of long-term capital and more effective use of experienced leadership talent.
Listen to discover:
- How to assess whether an overlooked pharmaceutical asset deserves a second life
- Why the development plan and financing plan must be designed together
- What founders should look for in an investment partner
- How Phase I trials can generate decision-quality evidence, not simply safety data
- Why biotech leadership is less about issuing decisions and more about building trust, alignment and candour
- What Europe needs to compete more effectively on the international biotech stage
● Feedback
● Subscribe (Get notified when new episodes are available. NO marketing!)

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.